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Abstract: 
New heteroaryl HIV-protease inhibitors bearing a carbamoyl spacer were synthesized in few steps 
and high yield, from commercially available homochiral epoxides. Different substitution patterns 
were introduced onto a given isopropanoyl-sulfonamide core that can have either H or benzyl 
group. The in vitro inhibition activity against recombinant protease showed a general beneficial 
effect of both carbamoyl moiety and the benzyl group, ranging the IC50 values between 11 and 0.6 
nM. In particular, benzofuryl and indolyl derivatives showed IC50 values among the best for such 
structurally simple inhibitors. Docking analysis allowed to identify the favorable situation of such 
derivatives in terms of number of interactions in the active site, supporting the experimental results. 
The inhibition activity was also confirmed in HEK293 mammalian cells and was maintained against 
protease mutants. Furthermore, the metabolic stability was comparable with that of the 
commercially available inhibitors. 
 
1. Introduction 
The AIDS epidemic is still one of the most challenging problems although great efforts are made to 
the discovery of new drugs for its treatment.
1
 Among many strategies to combat the disease, highly 
active antiretroviral therapy (HAART) containing at least one of HIV-1 protease inhibitors (PIs) is 
considered as the most effective treatment.
2
 
In fact, the HIV-1 aspartic protease (HIV-PR) is essential for the production of mature HIV 
particles and plays a key role in maintaining infectivity. Currently, nine approved PIs are 
 2 
commercially available and have definitely improved both the quality of life and life expectancy of 
HIV-infected patients. However, because of the rapid genomic evolution of the HIV, an inevitable 
consequence in the treatment of the infection has been the rise of drug resistance and therefore the 
dramatically reduction of the commercial inhibitors efficiency. 
Thus, both the emergence of highly mutated viral strains cross-resistant to antivirals and the 
occurrence of various debilitating side effects, and not last the high cost of HAART, prompted 
scientists to seek novel PIs, desirably with alternative frameworks.  
The last commercially available inhibitor, Darunavir, is actually the only one active against mutated 
virus; moreover, it is particularly interesting because of its double inhibitory activity: inhibition of 
the dimerization and inhibition of proteolytic activity.
3 
During our investigation on new peptidomimetics and non peptidic inhibitors, we found beneficial 
effect of heteroaryl rings as P2 ligand.
4
 
In particular, the systematic study on derivatives of simple substituted stereodefined 
isopropanolamine core showed the high effect of the functionality between the heteroaryl group and 
the core together with the type of heteroaryl group. Promising IC50 value was obtained with 
benzothienyl derivative 1 (Figure 1).4c With the aim to take advantage of an enhancement of H-
bond interactions, we synthesized in few steps and with high yield new simple benzofuryl, indolyl 
and benzothienyl HIV protease inhibitors 2 bearing a carboxyamide spacer, which in general 
showed in vitro activity against native protease, with IC50 values in the range of 1–15 nM. Such 
derivatives also showed inhibition activity in mammalian cells, demonstrating their promising 
potential.
5
 
 
 
Figure 1 
 
In our recent studies,
4a 
some carbamoyl structures containing indole ring as heteroaryl mojety 
(compound 3, figure 2) were examined, but the biological activity resulted only in the Mrange. 
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As it can be seen, compound 3 bears the carbamoyl group, which is reversed respect to the well-
known Darunavir and TMC-126  
 
Figure 2 
 
Thus, following the concept of targeting the protein backbone, with the aim to design simple non-
peptidic heteroaryl structures, we planned a systematic study on the synthesis and inhibition activity 
of new derivatives with general structure A, in which the heterocycle is spaced from the core by a 
carbamoyl function in the same disposition of Darunavir and TMC-126. The type of heteroaryl 
group (X = O, NH, S) and the core were modified, with the presence of either H or benzyl as R 
substituent. 
 
Figure 3 
 
 
2. Results and Discussion 
 
Chemistry 
For the preparation of simple unsubstituted isopropanolamine core (R = H in figure 3), in 
consideration of our previous research,
4
 the synthetic route started from the commercially available 
bidentate electrophile (S)-glycidol 4 (Scheme 1). 
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Scheme 1. Synthesis of inhibitors 10a-c: (a) i-BuNH2, i-PrOH, rt, 24h (quant.); (b) 2 eq. 4-
methoxybenzenesulfonyl chloride, Et3N, CH2Cl2, rt, 24h; (c) NaN3, DMF, reflux (80% yield from 
4); (d) H2, Pd/C 10%, EtOH, rt, 4h; (e) 5-hydroxyheteroarenes 9a-c, p-nitrophenylchloroformiate, 
Et3N, DCM, 1h, rt; then 8, rt, 24h (10a, 74%, 10b, 72%, 10c 72%). 
 
(S)-Glycidol was first reacted with isobutylamine in isopropanol to achieve aminodiol 5, which was 
successfully treated with p-methoxybenzenesulfonyl chloride and triethylamine in dry CH2Cl2 to 
obtain sulfamido-sulfonate 6. This compound underwent to nucleophilic displacement with NaN3, 
to give the sulfamidyl-azide 7, which was then reduced to amine 8 by catalytic hydrogenation. In 
the last step, the suitable heteroaryl-carbamoyl group was introduced by a reaction with different 
carbonates 11a-c, which were formed in situ from the corresponding 5-hydroxyheteroarene 9a-c 
and p-nitrophenylchloroformate. (Scheme 2) 
 
 
Scheme 2. Synthesis of intermediates 11a-c 
 
While 5-hydroxyindole 9c is cheaply available, 5-hydroxybenzofuran 9a and 5-
hydroxybenzothiophene 9b had to be prepared, due to their high cost. Unfortunately, only few 
 5 
methods are reported in literature.
6
 In particular, those starting from 4-methoxyphenol 12a or 4-
methoxythiophenol 12b usually give low overall yield, due to the cyclization step. Hence, we 
successfully revisited such procedure, using bromodiethylacetal in the alkylation step and 
Amberlyst-15
7
 in the subsequent cyclization/aromatization step. (Scheme 3). 
By these modifications 5-methoxy-heteroarenes 14a-b were obtained in good yield (> 60% in two 
steps from 12a-b). Demethylation of 14a-b afforded to desired 5-hydroxyheteroarenes 9a-b in high 
yield, making such three steps procedure the best one reported, in terms of overall yield (> 49% 
yield from 12a-b). 
 
 
Scheme 3. Synthesis of heteroarenes 9a-b: (a) 4-methoxy(thio)phenol 12a or 12b, 
BrCH2CH(OEt)2, Cs2CO3, MeCN, reflux, 40h (13a, 78%; 13b, 81%); (b) 12a-c, Amberlyst-15, 
chlorobenzene 120°C, 3h (14a, 78%; 14b, 75%); (c) BBr3SMe2 1M in CH2Cl2, chlorobenzene 
120°C, 24h (9a, 80%; 9b, 81%). 
 
The preparation of benzyl substituted derivatives (with R = Bn in structure A, figure 3) was even 
shorter, taking advantage of established chemistry
8
 and using homochiral N-Boc protected amino 
epoxide 15. The epoxide was firstly opened with iso-butylamine to afford the monoprotected 
diaminoalcohol 16 (scheme 4). Then, the p-methoxyphenylsulfonyl group was introduced and the 
N-Boc group efficiently displaced by TFA. The crude ammonium trifluoroacetate derivative was 
treated with NEt3, affording the free amine 18. From this common intermediate, we were easily able 
to achieve new inhibitors 19a-c by reaction of amine 18 with the in situ preformed carbonates 11a-c 
of the starting phenols 9a-c. 
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Scheme 4. Synthesis of inhibitors 19a-c: (a) i-BuNH2, i-PrOH, 60°C, 4h (>99% yield); (b) 4-
methoxybenzenesulfonyl chloride, Et3N, CH2Cl2, rt, 24h; (c) TFA/CH2Cl2 30%, rt, 1 h; then Et3N 
(84% yield from 16); (d) 5-hydroxyheteroarenes 9a-c, p-nitrophenylchloroformiate, Et3N, CH2Cl2, 
1h, rt; then 18, rt, 24h (19a, 75%; 19b, 71%; 19c 70%). 
 
It is to be highlighted that this synthetic pathway appears very solid, high yielding and general, 
irrespective on the N-alkyl group, the sulfonamide or the type of heteroaryl moiety chosen. The 
easy access of common intermediates represents an open door to different target molecules with 
pharmacological activities even beyond the inhibition of HIV-protease.
9
 
Biological assays were carried out on all the prepared compounds both in vitro and in mammalian 
cells, as described in the next section. 
 
In vitro activity  
IC50 values were obtained on recombinant wild type HIV protease (Table 1) by measuring the initial 
rates of hydrolysis of the fluorogenic substrate Abz-Thr-Ile-Nle-Phe(NO2)-Gln-Arg as previously 
reported
5
. 
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Table 1. Biological data (IC50, CC50 and Clearance) of the synthetized inhibitors 
Entry Structure IC50 (nM) CC50 (M) Clearance (µL/min/mg protein): 
a) human liver microsome 
b) rat liver microsomes 
1 10a 15400 ± 500  / 
2 10b 49±7 >100 / 
3 10c 13400 ± 220  / 
4 19a ≤ 0.6* >100 a) 121 
b) 26.8 
5 19b 10.8 ± 1.2 n.d. n.d. 
6 19c ≤ 0.6* 2.8 a) 548 
b) 522 
(*) as these values are very close to one half of the enzyme concentration used in the assay, they 
should be regarded as estimated upper limits. 
 
As it can be seen, compounds 19a and 19c are the most powerful inhibitors on the list, their IC50 
values being as less that 0.6 nM. Their activity is therefore higher than that of their corresponding 
amides, described in our previous work.
5
 
On the other hand, when the benzyl side chain at P1’ is lacking, as in compounds 10a-c, the activity 
is largely lost, with the exception of benzothienyl derivative 10b. Under this point of view, this 
series of carbamates behaves differently from the previous series of amides, where also the 
benzofurane derivative corresponding to 10a was found to inhibit the enzyme with an IC50 value of 
1 nM. 
In order to explain such results, we carried out a series of docking runs on carbamates 19a, 19c and 
10a, 10c. The calculation was carried out with Autdock Vina.
10
 The best poses were further refined 
by MD runs, which were carried out with the Gromacs package.
11
 
Despite the longer linker connecting the heteroaryl moiety with the core unit of the inhibitors, both 
19a and 19c can interact very well with the S2’ subsite, and the number of favorable interactions is 
indeed the same obtained with the corresponding amides already described,
Errore. L'origine riferimento non 
è stata trovata.
 as there is room enough in the site. Moreover, the benzofuran system of 19a could 
accept hydrogen bonding from Asp130 either at its side chain or at its backbone NH (Figure 4A, 
table 2). The lack of a methoxy group in comparison to the amides at the other side of the molecule 
has no effects on binding, most likely because this group was partly exposed to the solvent and not 
involved in interactions in the previous series of compounds. On the contrary, when the benzyl 
 8 
group is removed from the molecules as in 10a and 10c, two main docking solutions are found, but 
both fail to reach the maximum number of interactions attainable with the amides or with reference 
inhibitors as Amprenavir. In the first option, the heterocyclic side chain is still found inside S2’, 
with similar interactions, but of course the S1’ subsite is completely empty. The second solution is 
similar to that obtained in our previous work
5
 on the compounds lacking of the benzyl group, but 
this time the connecting chain is too long, and the aromatic system is largely exposed to the solvent 
outside the catalytic site of the enzyme, without recovering favorable interactions, as it can be 
clearly seen in the top view of Figure 4B and in table 2. 
 
 
A 
 
B 
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Figure 4. A: overlay of the optimized complex of HIV-protease with compound 19a (green) with 
that of corresponding benzofuryl amide (red). B: top view of the overlay of the best docking 
solutions for compound 10a (green and blue) with the corresponding amide (red). 
Table 2. Number of favorable contacts established by the inhibitors at the S1’ and S2’ of the 
protease. 
Inhibitor S1’ S2’ 
Amprenavir 4 11 
 
2 
2 9 
 
10a 
0 8 
 
19a 
2 9 
 
Provided the presence of a new carbamoyl moiety, which makes these new compounds completely 
non peptidic, a preliminary study on the clearance was realized, in particular on inhibitors 19a and 
19c. It is well known that all HIV-1 Pr inhibitors which are currently on the market, except 
Ritonavir, undergo rapid degradation by cytochrome CYP3A and therefore require Ritonavir during 
their administration, to slow down their disposal. The tests were performed using human liver 
microsomes in the absence of Ritonavir as a booster. The results are reported in previous Table 1. 
As it can be seen the metabolic stability data of 19a are generally in line with those reported in the 
literature
12
 on the commercially available inhibitors. In fact, this new compound presents an 
intrinsic in vitro clearance ranging from 26.8 to 121 L / min / mg. On the other hand the intrinsic 
clearance shown by 19c was comparable only to that reported for Darunavir (from 522 to 548 L / 
min / mg), making this compound very promising. 
 10 
 
Biology 
 
All these new carbamate molecules were evaluated in their ability to inhibit the HIV-1 protease in 
mammalian cells, using a method developed by Lindsten et al.
13
 and already used in our previous 
work.
5 
Briefly, the expression of the precursor of HIV-1 protease bounded to green fluorescent 
protein (GFP) is toxic upon autocatalytic cleavage, determining the disappearance of the fluorescent 
signal. In the presence of a molecule with inhibitory activity, the signal due to the intact GFP-PR 
chimera becomes detectable and useful to monitor the in vivo inhibition of the enzyme. 
To use properly the molecules, we initially evaluated their possible cytotoxicity towards HEK293 
cells using the MTT dose-dependent viability assay. Our results determined a value of CC50 > 60 
μM for all the inhibitors, after 24 hours of exposure to 10a-c and 19a-c molecules (data are reported 
in Supplementary Materials). Therefore, the values of inhibitors concentrations used in all 
subsequent assays did not compromise cell viability. 
The quantitative analysis of the fluorescence signal given by the GFP-PR chimera, possibly 
inhibited by the 10a-c and 19a-c molecules, was performed by FACS analysis of the transfected 
cells, while the qualitative evaluation was performed by fluorescence microscopy. In detail, a weak 
background signal was detected in cells transfected with GFP-PR not treated with any inhibitor 
(Figure 5A, CTRL).  
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Figure 5. GFP-PR expression fluorescence analysis. A) FACS analysis of HEK293 cells transiently transfected with 
pcDNA3/GFP-PR and treated for 24h with HIV-1 protease inhibitors at indicated concentrations. CTRL stands for not 
inhibited HIV-1 protease expressing cells. Data are expressed as means ± standard error (SE) of three replicates from 
three independent experiments and were analyzed by one-way ANOVA followed by Dunnett's post hoc test using 
GraphPad Prism 7 software. *p<0.05, ***p<0.001. B) HEK293 cells expressing GFP-PR fusion protein were 
visualized by fluorescence microscopy after incubation with 30 µM of each inhibitor (10 µM for 19a) for 24 h. CTRL 
stands for not inhibited HIV-1 protease expressing cells and DRV indicates 10 µM Darunavir treatment (positive 
control). Images (40x magnification) are representative of three independent experiments. 
 
In contrast, cells transfected and treated with the commercial inhibitor Darunavir (DRV) showed a 
strong fluorescence signal, highlighting an optimal inhibition of the viral enzyme. Cells transfected 
and treated with each of the putative inhibitors showed a poor fluorescence signal relatively to the 
molecules 10a, 10b, 10c and 19b, evaluated both at 10 µM and at 30 µM of concentration (Figure 
5A), while a more than appreciable fluorescence signals were detected for the molecules 19a and 
19c. Of note, 19a molecule showed best activity at concentration of 30 µM, whereas 19c compound 
had best inhibition activity at 10 µM. These results have been confirmed by qualitative analysis of 
fluorescence intensity, performed at the most active concentrations of the inhibitors (Figure 5B). 
To evaluate the ability of the 19a and 19c molecules to be active also in the presence of some of the 
most common clinically significant drug-resistance mutations, we performed mutagenesis 
experiments on the wild type GFP-PR vector, providing the site-specific mutations V32I and 
 12 
V82A.
14
 As shown in figure 6A e 6B, the inhibitory activity of molecules 19a and 19c towards both 
variants of the HIV-1 protease is maintained almost unchanged compared to that shown against the 
wild type protease, suggesting that these mutations do not affect in any way their activity. 
 
 
Figure 6. Evaluation of HIV-1 protease variants inhibition. FACS analysis of HEK293 cells 
transiently transfected with pcDNA3/GFP-PR-V32I and with pcDNA3/GFP-PR-V82A and treated 
for 24h with HIV-1 protease inhibitors A) 19a and B) 19c, at 30 µM and 10 µM, respectively. Data 
are expressed as means ± standard error (SE) of three replicates from three independent 
experiments. 
 
3. Conclusion 
In conclusion, our results showed that some of the newly synthesized molecules have inhibitory 
activity against HIV-1 protease in mammalian cells, confirming, moreover, the data obtained in in 
vitro assays. Although they still are less active than the commercial inhibitor Darunavir, however, 
maintain this activity also towards variants of the protease.  
Furthermore, we can firstly highlighted that the presence of carbamate function makes these new 
compounds metabolically as stable as the most currently used inhibitors. In particular, benzofuran is 
apparently the heterocycle which confers greater metabolic stability. 
Considering the excellent biological activity, the very low cytotoxicity and the good clearance 
profile, compounds 19a and 19c represent very promising molecules. Being on track to counteract 
drug resistance encourages us to continue our studies, optimizing the chemical structure of HIV 
protease inhibitors to improve their properties as much as possible. 
 
Experimental section 
Chemistry 
Preparative chromatography was carried out on Merck silica gel (0.063–0.200 mm particle size) by 
progressive elution with opportune solvent mixtures. 
1
H and 
13
C NMR spectra were normally 
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carried out in CDCl3 solutions on a VARIAN INOVA 500 MHz or Bruker 400 MHz and referenced 
to CDCl3. Mass spectra were obtained with a Hewlett–Packard 5971 mass-selective detector on a 
Hewlett–Packard 5890 gas chromatograph [(OV-1 capillary column between 70 and 250 °C (20 °C 
min
-1
)]. The optical purity was evaluated by using a polarimeter JASCO Mod Dip-370. CH2Cl2 was 
dried by distillation over anhydrous CaCl2 in inert atmosphere. Dry THF and DMF were 
commercially available. 
 
(2R)-3-Isobutylamino-propane-1,2-diol (5) 
i-BuNH2 (8.0 mL, 80 mmol) was added to a stirred solution of (S)-glycidol 4 (0.308 g, 4.0 mmol) in 
i-PrOH (20 mL). The mixture was stirred at room temperature and after 24 h. Then the solvent and 
the excess of i-BuNH2 were removed under reduced pressure. The aminodiol 5 was obtained as oil 
in quantitative yield. 
1
H and 
13
C NMR spectra were
 
consistent to literature data.
4a 
 
(2R)-4-Methoxy-benzenesulfonic acid 2-hydroxy-3-[isobutyl-(4-methoxy-benzenesulfonyl)-
amino]-propyl ester (6). 
To a stirred solution of aminodiol 5 (0.115 g, 0.78 mmol) in anhydrous CH2Cl2 (40 mL), Et3N (0.28 
mL, 2.02 mmol) and 4-methoxybenzenesulfonyl chloride (0.384 g, 1.86 mmol) were added at room 
temperature and under Ar atmosphere. After 24 h the reaction was quenched with H2SO4 5% 
solution. Organic phase was washed adding saturated aqueous NaHCO3 solution and brine. The 
organic phases were collected, dried over Na2SO4, filtered and concentrated in vacuo. The crude 
containing compound 6 was used in the subsequent reaction without any purification. 
 
(2S)-N-(3-Azido-2-hydroxy-propyl)-N-isobutyl-4-methoxy-benzenesulfonamide (7). 
The product 6 (0.78 mmol) was dissolved in anhydrous DMF (10 mL) and NaN3 (0.104 g, 1.60 
mmol) was added at room temperarure and under Ar atmosphere. The reaction mixture was warmed 
at reflux and kept stirring for 4 h. The reaction was then quenched by adding H2O (20 mL). The 
mixture was then extracted with CH2Cl2 (3x30 mL) and the organic layer was dried with anhydrous 
Na2SO4, filtered and concentrated in vacuo. The crude was purified on silica gel (CH2Cl2/EtOAc 
98:2) and compound 7 was isolated as brown oil (0.219 g, 82% from 5). 
[α]20D = -8.0 (c 0.5, CH2Cl2)  
1
H NMR (400 MHz, CDCl3) δ (ppm): 7.73 (d, J = 6.8 Hz, 2H), 6.90 (d, J = 6.8 Hz, 2H), 4.03-3.92 
(m, 1H), 3.86 (s, 3H), 3.41-3.23 (m, 3H), 3.18-2.88 (m, 4H), 1.95-1.88 (m, 1H), 0.92 (d, J = 5.6 Hz, 
3 H), 0.85 (d, J = 5.6 Hz, 3H). 
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MS (m/z): 343 (MH
+
). Anal. Calcd. for C14H22N4O4S: C, 49.11; H, 6.48; N, 16.36; O, 18.69; S, 
9.36. Found C, 49.0; H, 6.5; N, 16.4; S, 9.4. 
 
(2S)-N-(3-Amino-2-hydroxy-propyl)-N-isobutyl-4-methoxy-benzenesulfonamide (8). 
Pd/C 10% (0.026 g) was added to a solution of compound 7 (0.171 g, 0.50 mmol) in EtOH (10 mL). 
The reaction mixture was stirred under H2 atmosphere at room temperature. After 4 h the reaction 
mixture was fluxed with Ar, filtered on a Celite path, washed with EtOH and concentrated in vacuo. 
The crude containing compound 8 was used in the subsequent reaction without any purification. 
[α]20D = -6.0 (c 0.5, CH2Cl2)  
1
H NMR (400 MHz, CDCl3) δ (ppm): 7.76 (d, J = 8.4 Hz, 2H), 6.99 (d, J = 8.4 Hz, 2H), 4.70 (s, 
2H), 4.10 (s, 1H), 3.88 (s, 3H), 3.79 (m, 1H), 3.38-3.36 (m, 2H), 3.10-2.80 (m, 2H), 2.74 (m, 2H), 
1.64 (m, 1H), 0.91 (d, J = 6.8 Hz, 3 H), 0.84 (d, J = 6.8 Hz, 3H). 
MS (m/z): 317 (MH
+
). Anal. Calcd. for C14H24N2O4S: C, 53.14; H, 7.65; N, 8.85; O, 20.23; S, 
10.13. Found C, 53.0; H, 7.4; N, 8.7; S, 9.8. 
 
Preparation of carbamates: general procedure. 
Et3N (0.033 mL, 0.24 mmol) and p-nitrophenylchloroformiate (0.048 g, 0.24 mmol) were added to 
a solution of 5-hydroxyheteroarenes 9a-c (0.24 mmol) in anhydrous CH2Cl2 (1 mL), under Ar 
atmosphere. The mixture was kept stirring at room temperature for 1 h to afford intermediates 11a-
c; then amine 8 (or 18) (0.20 mmol) was added and the mixture was kept stirring for 24h. The 
solvent was evaporated and the crude compounds were purified on silica gel (EP/EtOAc 97:3), 
affording to compounds 10a-c (or 19a-c). 
 
(2S)-{2-Hydroxy-3-[isobutyl-(4-methoxy-benzenesulfonyl)-amino]-propyl}-carbamic acid 
benzofuran-5-yl ester (10a). 
The product 10a was obtained as white solid (74% yield). [α]20D = +10.7 (c 0.5, CH2Cl2).
1
H NMR 
(500 MHz, CDCl3) δ (ppm): 7.75 (d, J = 8.8 Hz, 2H), 7.64 (d, J = 2.0 Hz, 1H), 7.46 (d, J = 8.8 Hz, 
1H), 7.35 (d, J = 2.0 Hz, 1H), 7.04 (dd, J1 = 8.8 Hz, J2 = 2.0 Hz, 1H), 6.99 (d, J = 8.8 Hz, 2H), 6.74 
(brs, 1H), 3.99 (bs, 1H), 3.86 (s, 3H), 3.60 (m, 2H), 3.35 (m, 1H), 3.14 (A of ABX system, JAB = 
15.1 Hz, JAX = 4.8 Hz, 1H), 3.04 (B of ABX system, JAB = 15.1 Hz, JBX = 7.3 Hz, 1H), 2.90 (d, J = 
7.8 Hz, 2H), 1.88 (m, 1H), 0.93 (A of AB system, JAB = 6.8 Hz, 3H), 0.92 (B of AB system, JAB = 
6.8 Hz, 3H). 
13
C NMR (125 MHz, CDCl3) δ (ppm): 163.1, 156.5, 152.4, 146.5, 146.3, 146.1, 129.6, 
129.6, 129.4, 127.9, 118.2, 114.4, 113.7, 111.6, 106.8, 69.9, 59.1, 55.5, 53.1, 44.1, 27.19, 20.1, 
 15 
19.8. MS (m/z): 477 (MH
+
). Anal. Calcd for C23H28N2O7S: C, 57.97; H, 5.92; N, 5.88; O, 23.50; S, 
6.73. Found C, 57.8; H, 5.7; N, 5.9; S, 6.6. 
 
(2S)-{2-Hydroxy-3-[isobutyl-(4-methoxy-benzenesulfonyl)-amino]-propyl}-carbamic acid 
benzo[b]thiophen-5-yl ester (10b). 
The product 10b was obtained as white solid (72% yield). [α]20D = 4.5 (c 0.5, CH2Cl2).
1
H NMR 
(500 MHz, CDCl3) δ (ppm): 7.84 (d, J = 8.6 Hz, 1H), 7.76 (d, J = 8.8 Hz, 2H), 7.59 (d, J = 2.1 Hz, 
1H), 7.49 (d, J = 5.4 Hz, 1H), 7.29 (d, J = 5.4 Hz, 1H), 7.13 (dd, J1 = 8.8 Hz, J2 = 2.1 Hz, 1H), 6.99 
(d, J = 8.8 Hz, 2H), 5.81 (bs, 1H), 4.01 (bs, 1H), 3.87 (s, 3H), 3.61 (m, 2H), 3.36 (m, 1H), 3.14 (A 
of ABX system, JAB = 15.1 Hz, JAX = 4.9 Hz, 1H), 3.05 (B of ABX system, JAB = 15.1 Hz, JBX = 
7.2 Hz, 1H), 2.90 (d, J = 7.9 Hz, 2H), 1.89 (m, 1H), 1.63 (bs, 1H), 0.93 (A of AB system, JAB = 6.8 
Hz, 3H), 0.92 (B of AB system, JAB = 6.8 Hz, 3H).
13
C NMR (125 MHz, CDCl3) δ (ppm): 163.1, 
156.3, 148.3, 140.3, 136.7, 129.7, 129.5, 128.1, 123.7, 122.9, 118.7, 115.9, 114.4, 69.9, 59.1, 55.6, 
53.2, 44.2, 27.4, 20.1.MS (m/z): 493 (MH
+
). Anal. Calcd for C23H28N2O6S2: C, 56.08; H, 5.73; N, 
5.69; O, 19.49; S, 13.02. Found C, 56.2; H, 5.5; N, 5.7; S, 13.2. 
 
(2S)-{2-Hydroxy-3-[isobutyl-(4-methoxy-benzenesulfonyl)-amino]-propyl}-carbamic acid 1H-
indol-5-yl ester (10c). 
The product 10c was obtained as white solid (72% yield).[α]20D = 32.4 (c 0.5, CH2Cl2).
1
H NMR 
(500 MHz, CDCl3) δ (ppm): 8.32 (bs, 1H), 7.76 (d, J = 8.6 Hz, 2H), 7.37 (bs, 1H), 7.32 (d, J = 8.5 
Hz, 1H),  7.22 (bs, 1H), 7.00 (d, J = 8.6 Hz, 2H),  6.95 (d, J = 8.5 Hz, 1H), 6.52 (bs, 1H), 5.76 (bs, 
1H), 3.98 (bs, 1H), 3.86 (s, 3H), 3.60 (m, 1H), 3.35 (m, 1H), 3.16 (A of ABX system, JAB = 15.1 
Hz, JAX = 4.9 Hz, 1H), 3.04 (B of ABX system, JAB = 15.1 Hz, JAX = 7.4 Hz, 1H),  2.91 (d, J = 7.4 
Hz, 2H), 2.18 (s, 3H), 1.89 (m, 1H), 0.94 (A of AB system, JAB = 5.9 Hz, 3H), 0.92 (B of AB 
system, JAB = 5.9 Hz, 3H).
13
C NMR (100 MHz, CDCl3) δ (ppm): 163.1, 157.1, 144.6, 133.6, 129.7, 
129.5, 128.1, 125.5, 116.3, 114.4, 112.7, 111.3, 102.9, 70.0, 59.1, 55.6, 53.2, 44.2, 27.4, 20.0.  
MS (m/z): 476 (MH
+
). Anal. Calcd for C23H29N3O6S: C, 58.09; H, 6.15; N, 8.84; O, 20.19; S, 6.74. 
Found C, 58.2; H, 6.2; N, 8.9; S, 6.7. 
 
(1R,2S)- (1-Benzyl-2-hydroxy-3-isobutylamino-propyl)-carbamic acid tert-butyl ester (16) 
i-BuNH2 (8.0 mL, 80 mmol) was added to a stirred solution of (2S,3S)-1,2-epoxy-3-(Boc-amino)-4-
phenylbutane 15 (1.053 g, 4.0 mmol) in i-PrOH (20 mL). The mixture was warmed at 60°C. After 
6h the solvent and the excess of i-BuNH2 were removed under reduced pressure. The product 16 
 16 
was obtained as white solid in quantitative yield. 
1
H and 
13
C NMR spectra were
 
consistent to 
literature data.
8
  
 
(1S,2R)-{1-Benzyl-2-hydroxy-3-[iso-butyl-(4-methoxy-benzenesulfonyl)-amino]-propyl}-
carbamic acid tert-butyl ester (17). 
To a stirred solution of aminoalcohol 16 (0.262 g, 0.78 mmol) in anhydrous CH2Cl2 (40 mL), Et3N 
(0.28 mL, 2.02 mmol) and 4-methoxybenzenesulfonyl chloride (0.192 g, 0.93 mmol) were added at 
room temperature and under Ar atmosphere. After 24 h the reaction was quenched with 5% aqueous 
H2SO4 solution. The organic layer was washed adding saturated aqueous NaHCO3 solution and 
brine. The organic phases collected were dried over Na2SO4, filtered and concentrated in vacuo. The 
crude was purified on silica gel (CH2Cl2/EtOAc 98:2) and compound 17 was isolated as white solid. 
1
H and 
13
C NMR spectra were
 
consistent to literature data.
8 
 
(2R,3S) N-(3-Amino-2-hydroxy-4-phenyl-butyl)-N-isobutyl-4-methoxy-benzenesulfonamide 
(18). 
To a stirred solution of 17 (0.395 g, 0.78 mmol) in anhydrous CH2Cl2 (29 mL), trifluoroacetic acid 
(13 mL) was added at room temperature. After 1 h the reaction mixture was concentrated, treated 
with toluene (3x20 mL) and evaporated under vacuum. The crude was purified on silica gel 
(CHCl3/CH3OH = 9:1) and the product 18 was obtained as white solid in 84% yield. 
1
H and 
13
C NMR spectra were
 
consistent to literature data.
8 
 
(1S,2R)-{1-Benzyl-2-hydroxy-3-[isobutyl-(4-methoxy-benzenesulfonyl)-amino]-propyl}-
carbamic acid benzofuran-5-yl ester (19a) 
Following the general procedure the compound 19a was obtained as white solid (75% yield). [α]20D 
= 17.5 (c 0.5, CH2Cl2). 
1
H NMR (500 MHz, CDCl3) δ (ppm): 7.65 (d, J = 8.7 Hz, 2H), 7.55 (d, J = 
2.4 Hz, 1H), 7.34 (d, J = 8.8 Hz, 1H), 7.25 (m, 4H), 7.20 (m, 1H), 7.11 (bs, 1H), 6.90 (d, J = 8.7 
Hz, 2H), 6.80 (d, J = 8.8 Hz, 1H), 6.64 (bs, 1H), 5.14 (d, J = 8.3 Hz, 1H), 3.87 (bs, 2H), 3.78 (s, 
3H), 3.74 (bs, 1H), 3.09 (dd, J1 = 15.1 Hz, J2 = 8.3 Hz, 1H), 3.01 (m, 2H), 2.92 (m, 2H), 2.75 (dd, 
J1 = 13.6 Hz, J2 = 6.8 Hz, 1H), 1.79 (m, 1H), 1.18 (bs, 1H), 0.87 (d, J = 6.5 Hz, 3H), 0.82 (d, J = 
6.5 Hz, 1H). 
13
C NMR (125 MHz, CDCl3) δ (ppm): 163.1, 155.2, 152.4, 146.4, 146.2, 137.5, 129.7, 
129.6, 129.5, 128.7, 127.9, 126.7, 118.1, 114.4, 113.6, 111.6, 106.8, 72.5, 58.9, 55.6, 55.2, 53.8, 
35.3, 27.3, 20.2, 19.9. MS (m/z): 567 (MH
+
). Anal. Calcd for C30H34N2O7S: C, 63.59; H, 6.05; N, 
4.94; O, 19.76; S, 5.66. Found C, 63.7; H, 6.1; N, 4.8; S, 5.6. 
 
 17 
(1S,2R)-{1-Benzyl-2-hydroxy-3-[isobutyl-(4-methoxy-benzenesulfonyl)-amino]-propyl}-
carbamic acid benzo[b]thiophen-5-yl ester (19b). 
Following the general procedure the compound 19b was obtained as white solid (71% yield). 
[α]20D = 14.2 (c 0.5, CH2Cl2). 
1
H NMR (500 MHz, CDCl3) δ (ppm): 7.78 (d, J = 8.5 Hz, 1H), 7.73 
(d, J = 8.6 Hz, 2H), 7.48 (d, J = 5.6 Hz, 1H), 7.42 (bs, 1H), 7.32 (m, 6H), 6.98 (d, J = 8.6 Hz, 2H), 
6.96 (d, J = 7.1 Hz, 1H), 5.40 (bs, 1H), 3.98 (bs, 2H), 3.85 (s, 3H), 3.14 (m, 3H), 3.00 (m, 2H), 2.85 
(dd, J1 = 13.4 Hz, J2 = 6.7 Hz, 1H), 1.88 (m, 1H), 1.76 (bs, 1H), 0.95 (d, J = 6.5 Hz, 3H), 0.91 (d, J 
= 6.5 Hz, 3H). 
13
C NMR (125 MHz, CDCl3) δ (ppm):163.1, 154.9, 148.0, 140.1, 137.5, 136.6, 
129.7, 129.5, 129.4, 128.6, 128.0, 126.6, 123.6, 122.8, 118.6, 115.8, 114.3, 72.5, 58.7, 55.6, 55.3, 
53.7, 35.3, 27.2, 20.1, 19.9. MS (m/z): 583 (MH
+
). Anal. Calcd for C30H34N2O6S2: C, 61.83; H, 
5.88; N, 4.81; O, 16.47; S, 11.01. Found C, 61.9; H, 5.7; N, 4.8; S, 11.1. 
 
(1S,2R)-{1-Benzyl-2-hydroxy-3-[isobutyl-(4-methoxy-benzenesulfonyl)-amino]-propyl}-
carbamic acid 1H-indol-5-yl ester (19c). 
Following the general procedure the compound 19c was obtained as white solid (70% yield).[α]20D 
= -18.2 (c 1.0, MeOH). 
1
H NMR (500 MHz, CDCl3) δ (ppm): 8.13 (bs, 1H), 7.65 (d, J = 8.8 Hz, 
2H), 7.36 (m, 4H), 7.20 (m, 3H), 7.13 (m, 2H), 6.89 (d, J = 8.8 Hz, 2H), 6.72 (d, J = 8.5 Hz, 1H), 
6.42 (bs, 1H), 5.09 (bd, J = 7.8 Hz, 1H), 3.85 (bs, 2H), 3.78 (s, 3H), 3.04 (m, 3H), 2.90 (m, 2H), 
2.76 (dd, J1 = 13.4 Hz, J2 = 6.5 Hz, 1H), 1.80 (m, 1H), 0.86 (d, J = 6.5 Hz, 3H), 0.83 (d, J = 6.5 Hz, 
3H).
13
C NMR (125 MHz, CDCl3) δ (ppm) 163.0, 155.8, 144.4, 137.5, 133.5, 129.8, 129.6, 129.5, 
128.6, 128.1, 126.6, 125.5, 116.2, 114.4, 112.7, 111.2, 102.9, 72.6, 55.6, 55.3, 53.8, 35.3, 27.3, 
20.0, 19.8.MS (m/z): 566 (MH
+
). Anal. Calcd for C30H35N2O7S: C, 63.70; H, 6.24; N, 7.43; O, 
16.97; S, 5.67. Found C, 63.8; H, 6.1; N, 7.4; S, 5.6. 
 
Modeling 
The docking runs were carried out on the reference pdb structure 3NU3, complex of wild type HIV 
protease with amprenavir. The ligand and water molecules were removed from the structure, while 
hydrogens and charges were added with MGLTools. The inhibitors molecules were prepared and 
optimized with the MMFF forcefield as implemented in Spartan 10 (Wave Function Inc.). The size 
of the docking grid was 65 x 50 x 40 Ǻ, comprising the whole protein. MD refinement of the 
complexes was carried out at 300 °K in the NTV ensemble with 500 ps runs. 
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Biology 
Dulbecco’s Modified Eagle Medium (DMEM), dimethyl sulfoxide (DMSO), 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and Darunavir were purchased from 
Sigma Aldrich (Milan, Italy). Trypsin-EDTA solution, Fetal Bovine Serum (FBS), glutamine, 
penicillin-streptomycin and Phosphate Buffered Saline (PBS) were purchased from Euroclone 
(Milan, Italy). QuikChange XL Site-Directed Mutagenesis Kit was purchased from Agilent 
Technologies. 
 
Cell culture and drug treatment 
Human embryonic kidney (HEK293) cells were maintained in DMEM supplemented with 10% 
FBS, 2 mM L-glutamine, 100 U/ml penicillin and 100 g/ml streptomycin at 37°C in a humidified 
incubator with 5% CO2. HIV-protease inhibitors were dissolved in DMSO to a stock concentration 
of 30 mM and diluted with complete DMEM to get the required concentrations. The final DMSO 
concentration in the cell cultures was no greater than 0.8%: this concentration does not affect cell 
viability. DMSO treated cells were used as control in all the experiments. 
 
Cell viability analysis 
Cell viability was determined considering that cells with active metabolism are able to convert 
MTT, a water-soluble tetrazolium salt, into a purple colored formazan product with an absorbance 
maximum near 570 nm
15
. Died cells lose the ability to convert MTT into formazan, thus color 
formation serves as a useful marker of only the viable cells. Briefly, HEK293 cells were plated in 
96-well plates at a density of 1 x 10
4 
cells/well and treated for 24 h with various concentrations of 
each HIV-1 protease inhibitor (12.5, 25, 50 and 100 M). Cells were then incubated with MTT 
solution (0.5 mg/ml in DMEM) for 4 h at 37°C. The formazan crystals were finally dissolved in 
DMSO : isopropanol (1:1) solution. The absorbance was measured at a wavelength of 570 nm, with 
background subtraction at 630–690 nm, using a GLOMAX Multidetection System.  
 
Generation of HIV-1 protease variants 
HIV-1 protease mutants (V32I and V82A) were generated with QuikChange XL Site-Directed 
Mutagenesis Kit, according to the manufacturer’s instructions, using pcDNA3-GFP-PR as a 
template
16
. Mutagenic primers were designed using Quick Change Primer Design Program 
available online at www.agilent.com/genomics/qcpd/ and each mutation was verified by 
sequencing. 
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Cell Transfection, Fluorescence microscopy and flow cytometric analysis 
Transfection experiments in HEK293 cells were performed, as previously described
5
, by cationic 
lipid transfection reagent (Trans-IT 2020, Mirus) using 0.5 μg of the expression vectors pcDNA3-
GFP-PR (gift from Nico Dantuma, Addgene plasmid # 20253) and V32I and V82A variants. Cells 
were collected 24 hours after transfection. Where indicated, immediately after transfection, cells 
were treated with 10 µM or 30 µM of each HIV-1 protease inhibitor. Darunavir (DRV) 10 µM was 
used as positive control. For fluorescence microscopy, cells were grown on coverslips, fixed with 
4% paraformaldehyde in PBS and observed under a fluorescent microscope (Nikon 80i). Analysis 
of GFP fluorescence was carried out resuspending cells in PBS and detecting signal using a FACS 
Canto II flow cytometer (Ex/Em: 480/510 nm). 
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